证券之星消息，10月9日，生物经济（970038）指数报收于2386.01点，涨0.61%，成交285.28亿元，换手 率1.76%。当日该指数成份股中，上涨的有32家，深科技以10.01%的涨幅领涨，下跌的有18家，信立泰 以3.96%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 证券代码 | PARTIC A - 1 MACE I VERSE - 1 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.81% | 248.24 | 1.04% | | 3009.76 | | sz000661 | 长春高新 | 5.41% | 129.25 | -0.58% | | 527.26 | | sz300759 | 康龙化成 | 4.66% | 35.30 | -1.26% | | 627.70 | | sz002252 | 十肖史上 | 4.52% | 6.78 | 1.35% | | 450.06 | | sz300347 | 泰格医药 ...

新华财经圣保罗10月3日电（记者杨家和）巴西国家开发银行（BNDES）2号发布公告称，将与中国进 出口银行共同设立一支10亿美元的双边基金，通过购买债券或股权等方式投资巴西资本市场，重点将投 向能源转型、基础设施和数字经济等领域。 巴西国家开发银行成立于1952年，是巴西国家开发性金融机构。巴西国家开发银行与中国进出口银行已 于9月17日签署合作意向声明，为基金设立奠定制度基础。双方明确基金投资重点包括绿色低碳转型、 基础设施建设、生物经济、农业、矿业、数字经济与人工智能等新兴领域。 （文章来源：新华财经） 巴西国家开发银行投资规划与机构关系总监纳尔逊·巴尔博萨（Nelson Barbosa）当天在圣保罗举行的第 二届当代中国研究国际研讨会上表示，这是巴西与中国金融机构首次共同设立、以巴西货币雷亚尔作为 主要计价单位的双边基金，是中巴金融合作的重要里程碑，将进一步加强中巴经贸与金融合作，深化两 国在绿色转型与可持续发展方面的伙伴关系。 根据规划，该基金预计自2026年起在巴西投入运作。巴西国家开发银行出资约4亿美元，中国进出口银 行拟出资6亿美元。 ...

Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]

将投中网设为"星标⭐"，第一时间收获最新推送 穗城开坛，DDK到DDP的破局之道。 来源丨 投中网 9月26日，由邦勤资本与国药励展联合主办的 "从 DDK 到 DDP，医疗器械中国智造 2025" 核心技术主 题论坛在广州广交会堂圆满落幕。产业界领军者、学术界权威、医疗机构代表、金融投资专家及政企人士 齐聚一堂，围绕生物医药科技战略、器械集采优化、全球化布局、药械融合创新等关键议题深度研讨，为 中国医疗器械产业的高质量发展与全球突围建言献策。 主办方致辞 国药励展副总经理丁传军 先生 与邦勤资本总经理刘明宇博士的开场致辞，精准锚定了论坛的核心议题。 丁总表示，"DDK 到 DDP" （戴维斯双杀到戴维斯双击）的路径演进，是中国医疗器械产业从产品引 进、技术跟随走向自主创新、智能制造的缩影，这一转型不仅是产业迈向高端化的核心命题，更与 国 家"中国制造 2025" 战略形成深度呼应。在全球医疗科技加速迭代与国内健康需求升级的双重驱动 下，"掌握核心技术是竞争立足之本，实现 ' 中国智造 ' 是参与全球竞争的关键"。 刘明宇博士则从产业和资金的双重视角解读了行业转型的时代意义："DDK 到 DDP 的跨越，不仅 ...

生物经济（970038）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.82% | 237.15 | 0.91% | 2875.30 | > 医药生物 | | sz002252 | 十麻原上 | 4.71% | 6.75 | -0.30% | 448.06 | 医药生物 | | sz300347 | 泰格医药 | 4.69% | 59.11 | 0.61% | 508.95 | 医药生物 | | sz000661 | 长春高新 | 4.34% | 122.10 | -2.49% | 6 498.09 | 医药生物 | | sz300759 | 康龙化成 | 3.99% | 35.25 | 0.69% | 626.81 | 医药生物 | | sz002714 | 牧原股份 | 3.85% | 53.56 | -1.51% | 2925.86 | 农林牧渔 | | sz300896 | 爱美客 | 3.7 ...

Group 1 - The Biotech Index (970038) closed at 2403.29 points, down 0.55%, with a trading volume of 25.269 billion yuan and a turnover rate of 1.59% [1] - Among the index constituents, 11 stocks rose, led by Jingxin Pharmaceutical with a 2.67% increase, while 38 stocks fell, with Yaoshi Technology leading the decline at 5.11% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, with a weight of 13.82% and a market cap of 290.246 billion yuan, and other notable firms like Tigermed and Changchun High-tech [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 1.789 billion yuan, while retail investors saw a net inflow of 1.354 billion yuan [3] - Specific stocks like Boteng Co. experienced a net inflow of 73.5819 million yuan from main funds, while others like Jiayin Pharmaceutical saw a net outflow of 4.8669 million yuan [3] - The overall trend indicates a mixed sentiment among institutional and retail investors, with significant movements in individual stocks reflecting varying levels of confidence [3]

Group 1 - The event "Exploring the Trillion-Yuan Biomanufacturing Synthesis Code" aims to showcase Shandong's biomanufacturing innovations and industry advantages, enhancing brand influence and accelerating new productivity development [1][4] - Shandong is recognized as a leader in biomanufacturing in China, with the most diverse product types and significant international standing [4][11] - The biomanufacturing industry in Shandong has achieved a unique advantage characterized by scale, complete supply chains, and active innovation, with several key products holding the world's largest production capacity [8][11] Group 2 - The provincial government plans to strengthen policy support and complete the "14th Five-Year" development plan for the biomanufacturing industry by the end of the year [8] - The industry is projected to exceed a production value of 680 billion yuan in 2024, with significant contributions to green products and carbon emission reductions [11] - Leading companies in the biomanufacturing sector, such as Huaxi Biotechnology Co., Ltd. and Shandong Bailong Chuangyuan Biotechnology Co., Ltd., shared their achievements and experiences during the event [16]

0:00 秋色初染，松花江畔，碧波轻抚堤岸，夕阳为松浦大桥镀上一层金晖。 水波荡漾间，松花江沿岸的百年历史风貌与现代都市景致交相融合，以这条江为轴线，江两岸产业兴、生态 美、万物生的鲜活图景，正沿着广袤的黑龙江大地舒展铺陈。 松花江畔。人民网 徐成龙摄 "十四五"以来，黑龙江省持续提升粮食综合生产能力。2024年，全省粮食总产量达到1600.34亿斤，创历史新 高，连续15年位居全国第一，粮食总产量和增量均居全国首位。 全省新建重点文旅项目400多个，累计完成投资720亿元。2024年，全省接待游客量2.8亿人次、游客总花费 3701.2亿元，同比分别增长29.1%、67.1%。 踏上观景台，只见先进的自动遥感无人机方舱及地面监测设备已经投入运行，无人机的自动巡航监测结合风 云卫星遥感数据系统，形成了"卫星宏观监测、无人机中观巡护、地面仪器精准采集"的"空—天—地"三维立体农 情监测体系，为这片孕育中的稻海注入了科技的"生命力"。 "近年来，富锦市大力发展农业新质生产力，推动卫星遥感与农业的深度融合。未来，我们将持续促进科技攻 关与产业应用协同，为农业插上'科技的翅膀'。"富锦市委副书记、市长赵尉凯介绍。 当 ...

证券之星消息，9月15日，生物经济（970038）指数报收于2418.21点，涨0.91%，成交345.84亿元，换手 率2.15%。当日该指数成份股中，上涨的有21家，福瑞股份以20.01%的涨幅领涨，下跌的有29家，华大 基因以3.11%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 13.82% | 239.60 | -0.58% | 2905.01 | r 医药生物 | | sz002252 | 十肖史上 | 4.71% | 6.84 | 0.15% | 454.04 | 医药生物 | | sz300347 | 泰格医药 | 4.69% | 61.77 | 1.25% | 531.86 | 医药生物 | | sz000661 | 长春高新 | 4.34% | 126.81 | 0.88% | 517.31 c | 医药生物 | | sz300759 | 康龙化成 ...

Core Viewpoint - China's biomanufacturing and biotechnology sectors are experiencing significant growth, with advancements in CAR-T cell therapy, biopharmaceuticals, and digital pathology, positioning the country as a global leader in these fields [3][5][10]. Group 1: Biopharmaceuticals - China ranks second globally in the number of CAR-T clinical research centers, with 388 centers as of 2024, reflecting a 60% increase from 2020 [7]. - The biopharmaceutical market in China has surpassed 1.1 trillion yuan, with the number of new drug approvals reaching a five-year high of 93 in 2024 [6][7]. - China is now the second-largest biopharmaceutical market globally, with a significant number of drugs in development, narrowing the gap with the United States [7]. Group 2: Biotechnology and Innovation - The report highlights that China leads globally in biotechnology patent applications and research personnel, with over 30% of new innovative drugs and research pipelines originating from the country [5][11]. - The establishment of 23 biomanufacturing bases across the country indicates a robust infrastructure supporting the growth of the biomanufacturing sector [5]. - The "National Innovative Drug Insight System" was launched to enhance the efficiency of drug development and address challenges in identifying quality projects and matching strategic resources [9]. Group 3: Digital Pathology and Medical Devices - The Hubei Pathology Big Data Database has become the second-largest globally, with 170,000 high-precision digital slices, expected to exceed 500,000 by the end of 2025 [8]. - China leads the world in medical device patent applications, accounting for nearly 70% of the global total, showcasing its strong research output in this field [8]. Group 4: Agricultural Biotechnology - The agricultural biotechnology market in China accounts for 23% of the global market, with significant advancements in genetically modified crops [12]. - The application of synthetic biology and gene editing is driving growth in biomanufacturing, with a focus on biopharmaceuticals, biomaterials, and bioenergy [12]. Group 5: Future Outlook - The global biomanufacturing market is projected to grow significantly, with estimates suggesting a rise from $4-5 trillion to $30 trillion by 2050, indicating a compound annual growth rate of 8.6% [11]. - The integration of artificial intelligence in life sciences is expected to enhance drug development efficiency and expand applications across various sectors, including healthcare and agriculture [12].